Europe Confronts Rising Competitive Pressure as China Accelerates Export-Led Growth 
Asia’s IPO Market Set for Strong Growth as China and India Drive Investor Diversification 
Australia’s Economic Growth Slows in Q3 Despite Strong Investment Activity 
U.S. Futures Steady as Rate-Cut Bets Rise on Soft Labor Data 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
Glastonbury is as popular than ever, but complaints about the lineup reveal its generational challenge 
Gold Prices Steady as Markets Await Key U.S. Data and Expected Fed Rate Cut 
Why a ‘rip-off’ degree might be worth the money after all – research study 
Germany’s Economic Recovery Slows as Trade Tensions and Rising Costs Weigh on Growth 
Dollar Weakens Ahead of Expected Federal Reserve Rate Cut 
USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates 
RBI Cuts Repo Rate to 5.25% as Inflation Cools and Growth Outlook Strengthens 
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative 
Oncologica has launched its Prostatefocus cancer genetic screening test that identifies men at increased risk of developing prostate cancer.
A significant proportion of men, particularly those people who develop aggressive life-threatening prostate cancer at a relatively early age, can now be identified as a consequence that they carry inherited abnormal disease-causing genes.
The family of inherited prostate cancer-causing genes is all involved in a process called DNA damage repair (DDR) which plays a critical role in ensuring that the DNA in your cells is maintained in a healthy state.
An inherited abnormality in any of these DDR genes predisposes men to the development of early aggressive prostate cancer. Notably, survival among men with faulty DNA repair genes is half that of men with normal DDR genes.
The new genetic Prostatefocus genetic screening test uses a simple saliva self-sample collection kit. Men who test positive can then benefit from regular checks, blood tests, and lifestyle preventative measures.
Dr. Marco Loddo, co-owner and scientific director at Oncologica, a leading genetic cancer and viral testing laboratory based in Cambridge UK, said that prostate cancer tends to grow slowly without symptoms, so men often present late with an advanced incurable disease.
Prostate cancer is more treatable when caught early so screening tests can help identify an individual at high risk of developing the disease so regular checks can take place.
The Prostatefocus test is available via Oncologica’s nationwide specialist medical healthcare providers who conduct a pre-test consultation explaining how the test works and the implications of any results.
